DE2057174A1 - Pharmazeutisches Produkt,insbesondere injizierbares Lokalanaesthetikum - Google Patents
Pharmazeutisches Produkt,insbesondere injizierbares LokalanaesthetikumInfo
- Publication number
- DE2057174A1 DE2057174A1 DE19702057174 DE2057174A DE2057174A1 DE 2057174 A1 DE2057174 A1 DE 2057174A1 DE 19702057174 DE19702057174 DE 19702057174 DE 2057174 A DE2057174 A DE 2057174A DE 2057174 A1 DE2057174 A1 DE 2057174A1
- Authority
- DE
- Germany
- Prior art keywords
- local anesthetic
- beta
- ppm
- methyl
- local
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003589 local anesthetic agent Substances 0.000 title claims description 23
- 239000000825 pharmaceutical preparation Substances 0.000 title description 3
- 229940127557 pharmaceutical product Drugs 0.000 title description 2
- 239000002876 beta blocker Substances 0.000 claims description 22
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 claims description 20
- 239000005526 vasoconstrictor agent Substances 0.000 claims description 12
- 239000004480 active ingredient Substances 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 102000012740 beta Adrenergic Receptors Human genes 0.000 claims description 3
- 108010079452 beta Adrenergic Receptors Proteins 0.000 claims description 3
- 229960001413 acetanilide Drugs 0.000 claims description 2
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 claims description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 claims 1
- 239000000243 solution Substances 0.000 description 17
- 230000000694 effects Effects 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 15
- 238000002690 local anesthesia Methods 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- 239000000126 substance Substances 0.000 description 9
- 230000003444 anaesthetic effect Effects 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- WJUUZHQWGKSLIJ-UHFFFAOYSA-N Bupranolol hydrochloride Chemical compound Cl.CC1=CC=C(Cl)C(OCC(O)CNC(C)(C)C)=C1 WJUUZHQWGKSLIJ-UHFFFAOYSA-N 0.000 description 6
- 230000000747 cardiac effect Effects 0.000 description 6
- 238000009101 premedication Methods 0.000 description 6
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 229960002748 norepinephrine Drugs 0.000 description 5
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 5
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 5
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000004087 cornea Anatomy 0.000 description 4
- 229960004194 lidocaine Drugs 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 206010003119 arrhythmia Diseases 0.000 description 3
- 229940097320 beta blocking agent Drugs 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 229960005015 local anesthetics Drugs 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000003193 general anesthetic agent Substances 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 229960003712 propranolol Drugs 0.000 description 2
- 239000003087 receptor blocking agent Substances 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- GEFQWZLICWMTKF-CDUCUWFYSA-N (-)-alpha-Methylnoradrenaline Chemical compound C[C@H](N)[C@H](O)C1=CC=C(O)C(O)=C1 GEFQWZLICWMTKF-CDUCUWFYSA-N 0.000 description 1
- 206010001540 Akathisia Diseases 0.000 description 1
- 241001605036 Anaesthetis Species 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 101100387923 Caenorhabditis elegans dos-1 gene Proteins 0.000 description 1
- 206010056476 Corneal irritation Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010015856 Extrasystoles Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GEFQWZLICWMTKF-UHFFFAOYSA-N Nordephrine Chemical compound CC(N)C(O)C1=CC=C(O)C(O)=C1 GEFQWZLICWMTKF-UHFFFAOYSA-N 0.000 description 1
- 206010033546 Pallor Diseases 0.000 description 1
- 208000000418 Premature Cardiac Complexes Diseases 0.000 description 1
- 241001526882 Strongylura timucu Species 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 208000006218 bradycardia Diseases 0.000 description 1
- 230000036471 bradycardia Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229960001807 prilocaine Drugs 0.000 description 1
- MVFGUOIZUNYYSO-UHFFFAOYSA-N prilocaine Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C MVFGUOIZUNYYSO-UHFFFAOYSA-N 0.000 description 1
- BJPJNTKRKALCPP-UHFFFAOYSA-N prilocaine hydrochloride Chemical compound [Cl-].CCC[NH2+]C(C)C(=O)NC1=CC=CC=C1C BJPJNTKRKALCPP-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19702057174 DE2057174A1 (de) | 1970-11-20 | 1970-11-20 | Pharmazeutisches Produkt,insbesondere injizierbares Lokalanaesthetikum |
| FR7141414A FR2115255B1 (OSRAM) | 1970-11-20 | 1971-11-19 | |
| GB5379571A GB1360820A (en) | 1970-11-20 | 1971-11-19 | Injectable local anaesthetic |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19702057174 DE2057174A1 (de) | 1970-11-20 | 1970-11-20 | Pharmazeutisches Produkt,insbesondere injizierbares Lokalanaesthetikum |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2057174A1 true DE2057174A1 (de) | 1972-05-25 |
Family
ID=5788691
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19702057174 Pending DE2057174A1 (de) | 1970-11-20 | 1970-11-20 | Pharmazeutisches Produkt,insbesondere injizierbares Lokalanaesthetikum |
Country Status (3)
| Country | Link |
|---|---|
| DE (1) | DE2057174A1 (OSRAM) |
| FR (1) | FR2115255B1 (OSRAM) |
| GB (1) | GB1360820A (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE7713618L (sv) * | 1977-12-01 | 1979-06-02 | Astra Laekemedel Ab | Lokalanestetisk blandning |
| US5234957A (en) * | 1991-02-27 | 1993-08-10 | Noven Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
| US5446070A (en) * | 1991-02-27 | 1995-08-29 | Nover Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
| US5332576A (en) * | 1991-02-27 | 1994-07-26 | Noven Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
-
1970
- 1970-11-20 DE DE19702057174 patent/DE2057174A1/de active Pending
-
1971
- 1971-11-19 FR FR7141414A patent/FR2115255B1/fr not_active Expired
- 1971-11-19 GB GB5379571A patent/GB1360820A/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| GB1360820A (en) | 1974-07-24 |
| FR2115255A1 (OSRAM) | 1972-07-07 |
| FR2115255B1 (OSRAM) | 1975-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69722401T2 (de) | Kombinationen von vasopressin und adrenergischen wirkstoffen zur behandlung des plötzlichen herztods | |
| DE69429536T2 (de) | Analgetisches Mittel und dessen Verwendung | |
| EP0754453B1 (de) | Lokalanästhetika zur topischen Therapie von Kopfschmerzen | |
| DE69814394T2 (de) | Verwendung von levobupivacain | |
| DE3005208A1 (de) | Verwendung von acylcarnitin in arzneimitteln zur behandlung von stoerungen im gehirn-metabolismus | |
| DE69432905T2 (de) | Verwendung von ketoconazol und verwandten substanzen in medikamenten für die behandlung des typ ii-diabetes | |
| DE2441191A1 (de) | Medizinische auftragsvorrichtung oder applikationsvorrichtung | |
| DE3304246C2 (OSRAM) | ||
| CH662945A5 (de) | Ophthalmische loesung. | |
| DE69033112T2 (de) | Zink enthaltende Sprays | |
| DE69814852T2 (de) | Verwendung von levobupivacaine in der pediatrischen chirurgie | |
| EP2323645A1 (de) | Verwendung niedrig-dosierter lokalanästhetika oder derivate davon zur therapie chronischer schmerzen, insbesondere migräne | |
| DE69133341T2 (de) | Zusammensetzungen und behandlungsverfahren für sympathisch unterhaltenen schmerz | |
| EP0758548B1 (de) | Lokalanästhetika zur topischen Therapie von Rückenschmerzen und Muskelverspannung | |
| DE2823174A1 (de) | Arzneimittel fuer die prophylaktische behandlung postoperativer tiefer venenthrombose | |
| DE4214953C2 (de) | Arzneimittel zur Erhöhung des Testosteronspiegels | |
| DE69110779T2 (de) | Schilddrüsenhormone zur kardialen behandlung. | |
| DE19519056A1 (de) | Verwendung von Antidepressiva zur Behandlung von Asthma und/oder Atemwegserkrankungen mittels inhalatorischer Applikation | |
| DD273977A5 (de) | Verfahren zur herstellung eines stomatologischen praeparates | |
| WO2003011340A1 (de) | Arzneiformulierung zur topischen anwendung für die therapie und prophylaxe von hyperhidrosis | |
| DE2057174A1 (de) | Pharmazeutisches Produkt,insbesondere injizierbares Lokalanaesthetikum | |
| DE69626312T2 (de) | Medikament zur linderung von schmerzen und zur förderung der entfernung von konkrementen bei urolithiasis | |
| DE2427732A1 (de) | Mittel zum anaesthesieren von saeugetieren | |
| DE69904297T2 (de) | Neue verwendung von ropivacain zur schmerzbehandlung | |
| DE2444652A1 (de) | Mittel zur bekaempfung lokaler schmerzen |